optinose
announces
preliminary
third
quarter
xhance
net
revenue
million
preliminary
xhance
net
revenue
growth
compared
third
quarter
compared
second
quarter
conference
call
webcast
held
november
eastern
time
yardley
globe
newswire
optinose
nasdaq
optn
pharmaceutical
company
focused
patients
treated
ear
nose
throat
ent
allergy
specialists
today
announced
preliminary
net
product
revenues
million
three
months
ended
september
xhance
net
product
revenues
increased
compared
three
months
ended
september
compared
three
months
ended
june
financial
information
preliminary
subject
change
company
expects
report
full
financial
results
third
quarter
corporate
updates
market
open
thursday
november
pleased
continued
growth
demand
xhance
evidenced
preliminary
third
quarter
net
product
revenues
million
stated
ceo
peter
miller
exceeding
third
quarter
net
revenue
threshold
specified
debt
facility
open
option
draw
additional
million
add
cash
position
would
extend
cash
runway
enable
us
continue
focus
growth
strategy
look
forward
providing
full
update
fifth
company
host
conference
call
members
company
leadership
team
host
conference
call
starting
eastern
time
thursday
november
discuss
financial
results
corporate
updates
participate
conference
call
please
dial
outside
addition
following
completion
call
telephone
replay
accessible
thursday
november
dialing
outside
entering
conference
id
simultaneous
webcast
call
presentation
accessed
visiting
investors
section
optinose
website
addition
replay
webcast
available
company
website
days
following
event
optinose
optinose
global
specialty
pharmaceutical
company
focused
serving
needs
patients
cared
ear
nose
throat
ent
allergy
specialists
learn
please
visit
follow
us
twitter
linkedin
cautionary
note
statements
press
release
contains
statements
within
meaning
private
securities
litigation
reform
act
statements
historical
facts
hereby
identified
statements
purpose
include
among
others
statements
relating
xhance
demand
preliminary
net
product
revenues
quarter
ended
september
growth
rate
prior
periods
option
draw
additional
million
company
debt
facility
drawn
potential
funds
extend
company
cash
runway
statements
regarding
company
future
operations
financial
performance
financial
position
prospects
objectives
future
events
statements
based
upon
management
current
expectations
assumptions
subject
number
risks
uncertainties
factors
could
cause
actual
results
events
differ
materially
adversely
indicated
statements
including
among
others
potential
preliminary
xhance
net
product
revenues
resulting
growth
rates
prior
periods
change
connection
finalization
company
financial
results
third
quarter
extent
duration
pandemic
impact
company
business
results
operations
financial
condition
physician
patient
acceptance
xhance
company
ability
maintain
adequate
reimbursement
xhance
market
access
company
ability
grow
xhance
prescriptions
net
revenues
unanticipated
costs
expenses
company
ability
comply
conditions
applicable
availability
million
draw
debt
facility
company
ability
comply
covenants
terms
facility
risks
uncertainties
factors
discussed
caption
item
risk
factors
elsewhere
company
recent
form
form
filings
securities
exchange
commission
available
result
cautioned
place
undue
reliance
statements
statements
made
press
release
speak
date
press
release
company
undertakes
obligation
update
statements
whether
result
new
information
future
developments
otherwise
optinose
investor
contact
jonathan
neely
